Lilly’s Tirzepatide Demonstrates Efficacy in Mid-Stage MASH Study

1. Mid-Stage Study Results: Eli Lilly's tirzepatide has shown positive results in a Phase 2 study for treating metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease.
2. Fibrosis Improvement: The study demonstrated that tirzepatide improved liver scarring (fibrosis) in patients with MASH, with 54.9%, 51.3%, and 51.0% of patients experiencing a greater than one-stage improvement in fibrosis without worsening of their disease at the lowest to highest doses, respectively.
3. Comparison to Placebo: The results were statistically significant compared to the 29.7% of patients on placebo who achieved this outcome.
4. Commercial Availability: Tirzepatide is currently approved for Type 2 diabetes and obesity under the brand names Mounjaro and Zepbound, respectively.
5. Potential Label Expansion: The study's results may support a potential label expansion for tirzepatide in MASH treatment.
6. Market Impact: The news has affected the stock of other companies involved in MASH treatment, such as Madrigal Pharmaceuticals, which saw a significant decline in its stock price.